Income Statement
AN2 THERAPEUTICS, INC.
ANTX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY |
|---|---|---|---|---|
|
Revenue
|
- | - | - | - |
|
Cost of Revenue
|
- | - | - | - |
|
Gross Profit
|
- | - | - | - |
|
Operating Expenses
|
38.11 | 56.79 | 69.64 | 42.26 |
|
Research & Development
|
24.77 | 40.49 | 54.87 | 28.51 |
|
Selling, General & Administrative
|
13.34 | 14.07 | 14.76 | 12.75 |
|
Other Operating Expenses
|
- | - | - | - |
|
Operating Income
|
-38.11 | -56.79 | -69.64 | -42.26 |
|
Non-Operating Income
|
- | - | - | - |
|
Interest Income
|
2.93 | 5.47 | - | - |
|
Interest Expense
|
- | - | - | - |
|
Other Non-Op Income / Expense
|
0.00 | - | 4.90 | -0.05 |
|
Income Before Tax
|
- | - | - | - |
|
Income Tax Expense
|
- | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - |
|
Net Income
|
-35.17 | -51.32 | -64.73 | -40.96 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY |
|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - |
|
EBITDA
|
-38.11 | -56.79 | -69.64 | -42.26 |
|
Earnings Per Share (Basic)
|
-1.16 | -1.72 | -2.74 | -2.79 |
|
Diluted EPS
|
-1.16 | -1.72 | -2.74 | -2.79 |
|
Weighted Average Shares
|
30.22 | 29.83 | 23.60 | 15.34 |
|
Diluted Weighted Avg Shares
|
30.22 | 29.83 | 23.60 | 15.34 |
|
Comprehensive Income
|
-35.15 | -51.57 | -64.08 | -41.30 |